Webinar on
Application of PAT Towards the
Development of 3D Printed Pharmaceutics (and Beyond)
Zoë Whalley1,2, Tom Mills1, Richard
Greenwood1, Patrick Wray2
1 School of Chemical Engineering,
University of Birmingham, B15 2TT.
2 Bristol Myers Squibb, Reeds Lane,
Moreton, Wirral, CH46 1QW.
3rd
April 2025 at 3pm (UK time)
The first FDA approved
3D-printed drug has only been on the market since 2015; this is currently an
area of significant research and development activity. A subject which is key
to understanding and controlling these novel manufacturing processes is Process
Analytical Technologies (PAT).
This research focuses on a type
of 3D Printing known as Fused Deposition Modelling (FDM). A filament is
produced by combining a polymer with an active pharmaceutical ingredient in a
hot melt extruder (HME). The printer then melts the filament and deposits it
onto a print bed layer by layer to form the 3D printed tablet.
New challenges exist at each stage of the production
processes including homogeneity, form change and assay, among others.
Consequently, it is necessary to develop our understanding of the impact and
outcomes of these processes. Vibrational spectroscopy, in conjunction with PAT,
can be used to monitor the entire manufacture and printing process, as well as
the long-term stability of the finished tablets. In this work, the benefits of
incorporating PAT into each manufacture stage are discussed, facilitating key
insights from the blend, to the filament, to the final 3D printed tablet
formulation.
This webinar will take no longer than one hour.
Please register directly at https://universityofstrathclyde.webex.com/weblink/register/r7b4f41efbad7936a50f9f87fd9caf51f